Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
1.320
-0.080 (-5.71%)
Mar 28, 2025, 4:00 PM EDT - Market closed
Outlook Therapeutics Employees
Outlook Therapeutics had 23 employees as of September 30, 2024. The number of employees decreased by 1 or -4.17% compared to the previous year.
Employees
23
Change (1Y)
-1
Growth (1Y)
-4.17%
Revenue / Employee
n/a
Profits / Employee
-$2,035,255
Market Cap
42.26M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
OTLK News
- 4 weeks ago - Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration - GlobeNewsWire
- 5 weeks ago - Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewsWire
- 6 weeks ago - Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment - GlobeNewsWire
- 2 months ago - Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors - GlobeNewsWire
- 2 months ago - Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD - GlobeNewsWire
- 2 months ago - Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - GlobeNewsWire
- 2 months ago - Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug - Benzinga